Skip to Main Content
Table 2—

Comparison of pharmacodynamic parameters for subjects using aspart and lispro

Pharmacodynamic parametersDay 1
PDay 4
P
AspartLisproDifference (95% CI)AspartLisproDifference (95% CI)
AUCGIR (mg/kg) 982 ± 83 919 ± 175 63 (−341 to 467) 0.76 839 ± 124 854 ± 116 15 (−354 to 325) 0.93 
GIRmax (mg · kg−1 · min−17.3 ± 0.6 6.4 ± 1.1 0.96 (−1.57 to 3.49) 0.46 7.7 ± 0.9 7.3 ± 1.0 0.39 (−2.38 to 3.16) 0.78 
TmaxGIR (min) 101 ± 9 92 ± 11 9 (−19 to 37) 0.53 79 ± 9 79 ± 7 0.14 (−23 to 22) 0.99 
Time to discontinuation of exogenous glucose (min) 263 ± 10 246 ± 15 16 (−21 to 54) 0.40 208 ± 20 214 ± 17 6 (−58 to 45) 0.81 
Ti50 (min) 58 ± 6 46 ± 5 12 (−3 to 27) 0.14 38 ± 4 39 ± 4 1 (−12 to 9) 0.79 
Td50 (min) 199 ± 13 191 ± 12 8 (−27 to 42) 0.66 136 ± 10 168 ± 13 32 (−64 to 0.58) 0.07 
Pharmacodynamic parametersDay 1
PDay 4
P
AspartLisproDifference (95% CI)AspartLisproDifference (95% CI)
AUCGIR (mg/kg) 982 ± 83 919 ± 175 63 (−341 to 467) 0.76 839 ± 124 854 ± 116 15 (−354 to 325) 0.93 
GIRmax (mg · kg−1 · min−17.3 ± 0.6 6.4 ± 1.1 0.96 (−1.57 to 3.49) 0.46 7.7 ± 0.9 7.3 ± 1.0 0.39 (−2.38 to 3.16) 0.78 
TmaxGIR (min) 101 ± 9 92 ± 11 9 (−19 to 37) 0.53 79 ± 9 79 ± 7 0.14 (−23 to 22) 0.99 
Time to discontinuation of exogenous glucose (min) 263 ± 10 246 ± 15 16 (−21 to 54) 0.40 208 ± 20 214 ± 17 6 (−58 to 45) 0.81 
Ti50 (min) 58 ± 6 46 ± 5 12 (−3 to 27) 0.14 38 ± 4 39 ± 4 1 (−12 to 9) 0.79 
Td50 (min) 199 ± 13 191 ± 12 8 (−27 to 42) 0.66 136 ± 10 168 ± 13 32 (−64 to 0.58) 0.07 

Data are means ± SE unless indicated otherwise.

Close Modal

or Create an Account

Close Modal
Close Modal